{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059734","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-05-13T10:35:21+00:00","discovered_at":"2026-05-13T10:40:00.270487+00:00","generated_at":"2026-05-13T10:42:10.706018+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses","bullets":["Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.","Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.","WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.","Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.","ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059734","json":"https://secwatch.observer/filing/0001104659-26-059734.json","markdown":"https://secwatch.observer/filing/0001104659-26-059734.md","text":"https://secwatch.observer/filing/0001104659-26-059734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/0001104659-26-059734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/apre-20260513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T10:42:10.706018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36d2e499fcd982c615e0207fc45f1e0009b4edeb","claim":"Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926059734/0001104659-26-059734-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}